Lenvatinib (E7080) is an orally active, multi-targeted tyrosine kinase inhibitor with potent antitumor activity. It primarily inhibits VEGFR1-3 (IC50s = 22, 4, and 5.2 nM, respectively), as well as other receptor tyrosine kinases including FGFR1-4, PDGFRα/β (IC50s = 46 and 51 nM), KIT (IC50 = 100 nM), and RET. It suppresses angiogenesis and tumor proliferation by blocking these signaling pathways. In preclinical models, lenvatinib significantly reduces tumor growth and induces tumor regression. Reagent grade, for research use only.
Usually ships within 24 hours.